Securities Law

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Groom Law Group adds top talent from DOL, HHS, and IRS, deepening its 'insider's view' on complex benefits and health regulations for clients.

Euromax Resources raised C$1.6M, but with 84% for overhead and only 9% for its stalled gold project, is this a step forward or just staying afloat?

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

After a 600%+ stock surge and an abrupt SEC trading halt, Charming Medical is now facing class action lawsuits alleging a social media manipulation scheme.

Leveraging a fleet of vintage F-104 jets, Starfighters Space raises $40M and goes public, aiming to disrupt the small satellite launch market.

After bombshell allegations and a stock plunge, Rezolve AI faces a major lawsuit investigation, raising critical questions about AI hype and corporate honesty.

From biopharma to webcomics, shareholder lawsuits reveal the perils of misleading investors. A look at four companies facing legal and financial fallout.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?

A logistics firm's stock soared 1,100% then collapsed overnight. Inside the alleged pump-and-dump scheme that reveals deep cracks in market integrity.

A class-action suit claims Primo Brands hid merger problems behind a perfect narrative. This is a deep dive into corporate spin and shareholder risk.

A class action lawsuit against Telix Pharmaceuticals reveals the perilous gap between optimistic corporate disclosures and harsh regulatory setbacks.

A promising fintech's complex arbitrage strategy collapses, triggering a stock crash, CEO exit, and a wave of securities fraud investigations.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.